Livagen vs Vilon
Moderate Research vs Moderate Research
compatible Different organ targets; can be combined in bioregulator protocols.
Molecular Data
Livagen Vilon
Weight 432 Da 275 Da
Half-life Not established Not established
Chain 4 amino acids 2 amino acids
Type Tetrapeptide bioregulator Dipeptide bioregulator
Key Benefits
Livagen
01 Significant hepatoprotective properties
02 Decondenses chromatin to activate genes
03 Restores liver function in hepatitis
04 Normalizes immune status
05 Improves antioxidant status
06 Activates ribosomal gene expression
07 Maximum effects occur during aging
08 Boosts protein synthesis and cell activity
Vilon
01 Increases mean lifespan 20-40% in animal models
02 Suppresses tumor development
03 Stimulates thymocyte proliferation
04 Activates T-helper cells
05 Restores chromatin structure in aged lymphocytes
06 Enhances intestinal barrier function
07 Improves enzyme activity in aged tissue
08 Part of comprehensive longevity protocols
Dosing Protocols
Livagen
10-20 mg daily / Daily for 10-20 days per cycle
Research protocol 10 mg Daily for 10 days
Vilon
10-20 mg per day (oral capsules) or 10 mg (injectable) / Daily for 10-20 consecutive days (Khavinson bioregulator cycle)
Research protocol 10 mg Daily for 10 days
Side Effects
Livagen
Generally well-tolerated
Minimal side effects reported
Vilon
Generally well-tolerated
Minimal side effects reported
Contraindications
Active liver emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Active autoimmune flares (consult physician)
Known hypersensitivity
Pregnancy or breastfeeding
Research Evidence
Livagen Vilon
Status Moderate Research Moderate Research
References 4 studies 4 studies
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.